To determine whether critical splanchnic artery hypoperfusion can provoke systemic shock and to identify the roles of the peripheral opioid and nitric oxide (NO) systems in this process, various degrees of superior mesenteric artery hypoperfusion (SMA-H) were produced in anesthetized adult rabbits (n=40), and hemodynamic and metabolic indices were measured. Metabolic acidosis and irreversible hypodynamic shock occurred with SMA-H at levels representing 25-20% of mean baseline SMA blood flow. In 112 other rabbits subjected to SMA -Hat 20 % (SMA -H20 %), we studied plasma NO and en kephalin (ENK) levels, cardiovasculaI' reactivity to selected physiological agonists, effects of ENKs on plasma NO levels, and effects of peripheral opioid receptor blockade and inducible NO synthase (iNOS) inhibition. SMA-H20% progressively increased systemic blood levels of NO and ENKs. Exogenous ENK administration accentuated SMA-H20%-induced increases in plasma NO levels, and their cardiovascular depressing effects were significantly greater when they were administered during SMA-H20 % (vs, administration under baseline conditions). Selective blockade of cardiovascular 8-opioid receptors improved hemodynamics, prevented shock irreversibility and reduced plasma NO levels; similar effects were obtained by selective iNOS inhibition. These findings demonstrate that critical arterial hypoperfusion of the gut can induce hypodynamic systemic shock through ENK-induced hyperactivation of cardiovascular 8-opioid receptors, which leads to increased plasma levels of NO related in part to increased iNOS activity. Since pronounced splanchnic artery hypoperfusion occurs in all advanced systemic shock states, selective 8-opioid receptor antagonists and/or iNOS inhibitors may prove to be useful in improving shock hemodynamics and metabolic derangements and/or preventing progression toward irreversibility.
Irreversible systemic shock is characterized by myocardial dysfunction, vascular hyporeactivity to endogenous or exogenous vasoconstrictor substances, and disruption of cell metabolism (1-3). Discouraging results have been obtained with treatment based on pharmacologic blockade of proinflammatory cytokines, eicosanoids, and other mediators that are released in large amounts during these states (4) (5) . Observations on the involvement of oxidative damage in systemic shock have prompted the development of new therapeutic approaches, that are currently being assessed. In fact, oxygenderived free radicals (e.g., superoxide), high-energy oxidants (e.g., peroxynitrite), and nitric oxide (NO) play critical roles in shock-related cell and organ dysfunction through mechanisms such as lipid peroxidation, inhibition of mitochondrial respiratory chain enzymes, inactivation of membrane sodium channels and Na,K-ATPase, and DNA single-strand breakage with poly(ADP-ribose) synthetase activation (2) . These considerations have prompted the use of NO synthase (NOS) inhibitors (i.e. nonselective Larginine analogs) and various antioxidant compounds in human shock states, but neither approach has reportedly produced a significant reduction in mortality (2, (6) (7) (8) . Numerous observations suggest that splanchnic ischemia (hypoperfusion) per se is capable of provoking systemic shock and that its recurrence duri ng establ ished shock states increases the risk of irreversi biIity. These effects are believed to be mediated by the release from splanchnic tissues of "toxic" humoral factors such as endotoxin, myocardial depressant factor (MDF), and other peptide-like substances, some of which are known stimulators of inducible NOS (iNOS) activity. Unfortunately, these hypotheses are based on evidence obtained in animal models of shock or human shock states, which do not allow controlled splanchnic hypoperfusion (i.e., of the celiac axis and/or the superior and/or inferior mesenteric arteries); for this reason, the critical levels of splanchnic blood flow (BF) that trigger the release of these mediators have never been identified (9) (10) (11) (12) (13) (14) . In addition, splanchnic artery occlusion-reperfusion (SAO) shock models, which involve a fixed interval of complete arterial occlusion followed by postischemic reperfusion, fai I to reprod uce the card iac depression and/or local arterial vasoconstriction that causes splanchnic hypoperfusion during various forms of systemic shock (2, 15) . The principal aim of the present study was to determine whether critical splanchnic artery hypoperfusion is indeed responsible for the hemodynamic and metabolic alterations that characterize systemic shock evolving to irreversibility. Our second objective was to establish whether these changes might be mediated by synergistic interactions between the peripheral opioid and NO systems. Indeed, opioid peptides, such as leu'i-and met'<enkephalins (ENKs), are abundant in intestinal tissues, and they are known to be released under conditions of splanchnic hypoperfusion (16) (17) . Moreover, at physiological plasma concentrations, ENKs markedly increase plasma NO levels by stimulating itsendothelial production from L-arginine, and both NO and ENKs play physiologic roles in the reduction of blood pressure (BP), heart rate (HR) and cardiac inotropism (18) (19) (20) (21) . Opioid and nitrergic mechanisms are reportedly involved in the hemodynamic impairment that characterizes endotoxin and acute hypovolemic shock states, and, at the central level, their actions appear to be synergistic. However, the evidence supporting these conclusions is based almost exclusively on observations of the beneficial effects (i.e., transient BP increase) of nonselective opioid receptor antagonists (e.g., naloxone) and/or NOS inhibitors (e.g., N-nitro-L-arginine methy I ester) together with the exacerbating effects of the NO precursor, Larginine, in cases of systemic shock (22) (23) (24) . There is no direct evidence (least of all in models of splanchnic hypoperfusion) that shock is associated with increases in plasma opioid peptide levels or that these peptides are responsible for the augmented circulating levels of NO concentrations seen in shock states. Indeed, meta-analyses have highlighted the limitations of current data supporting the use of opioid receptor antagonism and NOS inhibition for treatment of human shock (e.g., contradictory findings, frequent methodological weaknesses, and the absence of cost-benefit analyses, including mortality and adverse effects), and the authors of these reviews have concluded that it is premature to recommend these approaches (6) (7) 25) .
MATERIALS AND METHODS

Animals
The study was conducted on 152male New Zealand rabbits (3.3 -3.5 kg), which were randomly divided into 19 groups, each containing eight animals. Animal care protocols were consistent with European Community norms (806/609/CEE) and approved by the Animal Care and Use Committee of the Catholic University School of Medicine, Rome, Italy. Animals were sedated with intramuscular ketamine HCI (I I rug/kg, Abbott, Apri lia, Italy), and general anesthesia was induced and maintained with intravenous (i.v.) sodium pentobarbital (45 mg/kg, Abbott). Body temperature was kept constant as previously described (26) .
Surgery and cardiovascular monitoring
Following induction of anesthesia, tracheostomies were performed to ensure spontaneous room-air ventilation. Polyethylene catheters were inserted: (a) into the right femoral artery for BP monitoring; (b) the abdominal aorta (through the left femoral artery) for collection of arterial blood samples and for supplying blood to the perfusion pump (see below); (c) the left external jugular vein for central venous pressure (CVP) monitoring and collection of venous blood specimens; and (d) the left femoral vein for drug administration. BP (systolic, diastolic and mean) and CVP were monitored with P23/Db pressure transducers (Statham, Los Angeles, CA) and averaged electronically. The maximum rate of rise of the left ventricular isovolumetric pressure (dP/dt) was measured with a calibrated transducer-tip (3 French) catheter (Millar, Houston, TX), which was advanced into the left ventricle (through the left common carotid artery) and connected to a BL620 derivative computer (Biotronex, Kensington, MA). HR was measured as previously described (21, 26) .
Midline laparotomy was performed, and an electromagnetic flow probe attached to an SP 2202 flowmeter (Statham) was positioned around the aorta (about 0.5 ern below the origin of the left renal artery) for measuring systolic, diastolic, and mean BF. Stroke volume index (SVI) was obtained by integration of pulsatile aortic BF (ABF) with a BL 622 apparatus (Biotronex) (26) . Aortic vascular resistance (A VR) was calculated from mean BP and mean ABF values. Cardiovascular parameters were monitored polygraphically with minimized expression of preload and afterload, as previously described (27) (28) (29) . Sodium heparin (2500 units/kg) and dextran (0.4 g/kg) were infused intravenously (iv) (total volume: 5.8 ml/kg).
SMA hypoperfusion (SMA-H) procedure
The following method was used to achieve hypoperfusion of the SMA. Baseline values for all test parameters (Table I) were recorded when cardiovascular indices had stabilized at pre-laparotomy levels. Mean SMA BF was measured by an electromagnetic probe attached to the artery about I em below the origin of the inferior pancreatic-duodenal artery. At this point, the perfusion catheter was inserted into the SMA (Fig. I) , distal to the origins of the inferior pancreatic-duodenal, middle colic, dorsal cecal and ileo-colic arteries, which remained normally perfused throughout all experiments. In this way, supplementation from the celiac or inferior mesenteric circulations was avoided. The catheter was connected to a perfusion apparatus consisting in an Ismatec peristaltic pump (Sial, Rome, Italy) and a 15-ml reservoir primed with blood from the abdominal aorta (Fig. I) . The SMA was perfused at constant flow rates (ml/min) representing 100%, 50%, 25% or 20% of its mean baseline mean BF. Unless otherwise stated, hemodynamic parameters, metabolic indices and other determinations were remeasured 30 and 60 min after the initiation of continuous SMA perfusion, and every hour thereafter. Perfusion and monitoring were continued until death occurred or for a maximum duration of 7 hrs, at which point surviving animals were sacrificed by sodium pentobarbital overdose. Table I summarizes the SMA perfusion parameters and variables monitored in each of the 19 groups.
SMA hypoperfusion (SMA-H): Hemodynamic and metabolic characterization
Five groups of rabbits (Groups A-E, n=8 in each group) were used for these experiments, which were designed to identify the hemodynamic and metabolic features of various levels of SMA hypopcrfusion. SMA perfusion rates represented the following percentages of mean SMA baseline BF: 100% in Group A, 50% in Group B, 25% in Group C, and 20% in Group D. Group E (control) was subjected to surgical procedures alone. At the times specified above, hemodynamic parameters (BP, dP/dt, HR, ABF, and SVI) were recorded, and metabolic indices [arterial and venous p02(Ap02' Vp02)' pC0 2 (ApC0 2, VpCO), pH (ApH, VpH), hematocrit and arterial-venous difference in oxygen saturation] were determined in samples of aortic and jugular blood using standard techniques (26) (27) .
SMA-H20%-induced shock: Plasma levels of NO and ENKs
Two groups (F and G) of rabbits were used to investigate the relation between NO and ENKs under conditions of systemic shock provoked by SMA-H at 20% of baseline levels (SMA-H20%), found to induce systemic shock in Group D.
In Group F, hemodynamic parameters were recorded at the times specified above, and plasma levels of NO (as L-citrulline) were measured, as previously described (29, 30) , in l-rnl samples of jugular (i.e., systemic) blood collected at baseline and during SMA-H20% (0, 60, 120, 150 and 180 min). NO levels were also measured in portal (superior mesenteric) and suprahepatic blood samples to determine whether the hypoperfused tissues (the gut and/or the liver) contributed to NO changes in systemic blood levels.
In Group G, ENK levels were measured in jugular blood samples, as described elsewhere (31). At the same time points used for NO determinations in Group F, jugular blood was collected in tubes containing sodium citrate (3.8%) (9: I v/v) and stored at -20 Preliminary experiments on rabbits exposed to SMA perfusion at 100%, SMA-H50% or surgical procedures alone had revealed that jugular, portal and suprahepatic levels of NO, as well as jugular levels of ENKs, remained stable over ti me under each of these condi tions, and that the levels recorded in the three groups were not significantly different.
SMA-H20%-inducedsllOck: hemodynamic responses to physiological agonists
This set of experiments was conducted to compare hemodynamic responses to ENKs with those elicited by a series of physiological agonists believed to play roles in various shock states (2,3,5,9, 14). The rabbits of Groups H and I were exposed to SMA hypoperfusion at 20%, and hemodynamic parameters were monitored as described for Group F.
Physiological agonists were obtained as salts from Fluka (Buchs, Switzerland) and dissolved in saline. Doses were given i.v. in a volume of 50 Ill/kg within 30 min of preparation. Doses (u.g/kg, dose ratio = x 2.0) were expressed in terms of free bases. The substances tested in Group H were ENKs (12.5-50); noradrenaline (1.25-5); adrenaline (0.0625-0.25); angiotensin II (0.125-0.50) and bradykinin (BK, 0.625-2.50). Group I animals received ENKS (12.5-50); adenosine ; acetylcholine (0.315-1.25); serotonin (2.5-10) and histamine (1. . Substances were administered consecutively (in the orders given above) to all animals of each group, at baseline and during SMA-H20%, when hemodynamic and metabolic changes were evident, and peak responses were considered. All of the tested agonists arc known to have extremely short half-lives and they arc eliminated from the plasma via tissue uptake within few (venous-arterial) circulation times (29, 32) . Nonetheless, to further exclude the possibility of interference, drugs were administered only when cardiovascular parameters had rc-stahilized at values recorded prior to the administration of previously tested agonist (26, 28) . Even with these precautions, the total time required to test all test drugs (5 per group) under each condition (baseline vs. during SMA-H20%) was no more than 30 min. Under the latter condition, the first and last drugs tested were given 60 and ..s; 90 min, respectively, after the initiation of hypopcrfusion.
SMA-H2OClo-indliced shock: Effects of ENKs 011 plasma NO levels
In the previous set of experiments, ENKs (groups H, 1) were the only agonists that produced potentiated responses (reductions in BP, dP/dt and HR) during SMA-H20%, with respect to those produced under baseline conditions. Therefore, in Group J, jugular and portal levels of NO were measured at the point of maximal BP response to ENKs (12.5-5.0 ug/kg, i.e., the same doses used in Groups Hand 1) administered iv at baseline and 60, 120 and 180 min after the initiation of SMA-H20%.
SMA -H20%-indllced shock: Effects ofopioid receptor blockade and iNOS inhibition
This group of experiments was designed to evaluate the hemodynamic effects of opioid receptor blockade and inhibition of iNOS on SMA-H-induced shock. Four groups of rabbits (Groups K-N) were hypoperfused and monitored, as described for Group F. Test substances were infused continuously by i.v. route (0.275 ml/min) from the 60'h through the 120
Ll 1 minute after initiation of SMA-H20%. Group K (control) received 0.9% saline alone. In Group L, the infusion consisted of saline containing ICI 174864 (10 p.g/kg/min; N,N, diallyl-tyraib-aib-phe-Ieu-Oll, CRB, Harston, UK), a highly selective 8-opioid receptor antagonist that does not cross the blood-brain barrier (32) . Group M received naloxone HCI dihydrate (32) in sal ine (14 u.g/kg/rnin: FI uka), and
Group N was infused with AMT Of-Lg/kg/min; ±2-am ino-5 ,6-di hydro-6-methyl-4H-1 ,3-thiazi nc, HCI, Calbiochern, La Jolla, CA), a highly selective and reversible inhibitor of iNOS activity (33) , which is reportedly increased in NO-induced shock states (2, 6, 8) . In all four groups, jugular and portal NO levels were measured at baseline and during SMA-H20% (60, 120, 180 and 240 min.). The doses used in these experiments had been establ ished in prel iminary studies on anesthetized rabbits with 100% SMA perfusion. Under these conditions, the selected doses of ICI 174864 and naloxone produced (after 60 min of i.v. infusion) a reduction of about 60% in the hypotensive response (mean BP) to intravenous metvcnkcphalin (50 u.g/kg) without changing the mean baseline BP. The test dose of AMT had no significant effect on mean baseline BP and provoked only a slight decrease (about 6 %) in jugular NO levels before and during SMA perfusion (through the 240 lh min).
SMA -H20%-inducedsShock: hemodynamic effects of drugs
In the final group of experiments, we attempted to verify the specificity of the effects observed following opioid receptor blockade or iNOS inhibition. Five groups of rabbits (Groups O-S) were hypoperfused and monitored as described for Group F. Test drugs (Fluka) were infused continuously by i.v. route (0.275 ml/rnin) from the 60 th through the I 20 th minute after initiation of SMA-H20%. Group 0 (control) received 0.9% saline alone. Group P received fenoprofen hydrate calcium salt (3500 p.g/kg/min), which inhibits the synthesis of prostaglandins and thromboxanes. Group Q was infused with hydrocortisone hernisuccinate sodium salt (300 u.g/kg/min), which also inhibits leukotriene synthesis and cellular release of substances (e.g., lysosome proteases) reportedly involved in circulatory shock states. Groups Rand S both received selective opioid receptor antagonists, respectively, nor-binaltorphirnine HCl (30f.Lg/kg/min), which is selective for K receptors, and naltrindole HCl (15 p.g/kg/min), which is highly selective for the oclass. For all drugs, the doses used (expressed as free bases) far exceed those reported as effective (32) .
Statistical analysis
The general experimental design is shown in Table   I . All sets of data, presented as means ± SEM, were found to follow a normal distribution. "Post hoc" Dunnett's method for multiple comparisons with baseline values within a group and/or one-way analysis of variance or paired t-tests were used to evaluate differences between means. P values < 0.05 were considered to be significant.
RESULTS
SMA -H: hemodynamic and metabolicfeatures
All the rabbits of Groups A (100% perfusion) and B (50% perfusion) survived seven hours (420 min) ofSMA perfusion and were sacrificed thereafter. In Groups C (25% perfusion) and D (20% perfusion) SMA-H induced fatal shock in all 16 animals: deaths occurred after 240-300 min (Group C) and 180-240 min (Group D) of SMA-H. Survival times and indices of hemodynamic and metabolic statuses in Group E, exposed to surgical procedures alone, were not significantly different from those of Group A. There were no significant changes in hematocrit in any of the five groups. Figure) . In Group C, acidosis (VpH < ApH) preceded the changes in BP, dP/dt, HR, SVI and ABF. In Group D, onset of acidosis coincided with the appearance of alterations in ABF, AVR, dP/dt and HR, and BP began to drop 60 min later.
In both groups (C and D), peripheral extraction of oxygen peaked after 60 min of SMA-H, when cardiac output and A VR were decreased and augmented, respectively. In Group D, the decrease in Vp02 resembled that observed in hypodynamic systemic shock states (9, 10, 23) . VpCO, increased progressively from baseline values in -Groups C and D (D>C). ApC0 2 increased through the 60 th min (only in Group D). Ap02 increased in both groups (C>D), and this rise coincided with the development of acidosis and reduction of cardiac output. Fig. 3 shows the NO and ENK levels injugular blood specimens from Group F. NO increased progressively after the initiation of SMA-H20%, and after 180 min levels were approximately twice as high as those recorded at baseline (Fig. 3 ). An opposite trend was seen in portal and suprahepatic levels of NO (not shown in Fig. 3 ). These specimens were characterized by similar concentrations of NO that were significantly lower than those found in jugular samples: after 120 min of SMA-H20%, portal NO was 10.5±0.4 pmoles/ml; suprahepatic NO was 10.6±0.05 pmoles/ml; jugular NO was 28.4±0.6 pmoles/ml (means ± SEM, n=8 in all cases, P < 0.05).
SMA-H20%-induced shock: plasma levels of NO and ENKs
As shown in Fig. 3 , the increase in jugular levels of NO (documented in Group F) was paralleled by a progressive rise in jugular blood ENK levels (measured in Group G). This increase was already evident after 60 min of hypoperfusion, and it continued through the l80'h min. Hemodynamically, this interval was characterized by the development of arterial hypotension, bradycardia, decreasing dP/dt, SVI and ABF, and increase in the AVR (Fig.   2) . Table II shows peak hemodynamic responses to the ten physiological agonists tested in Groups H and I. I.v. infusion of ENKs before SMA-H20% (baseline) produced dose-dependent reductions in BP, dP/dt and HR. These changes were significantly greater when the ENKs were administered during SMA-H20% (groups H and I). In contrast, cardiovascular responses to noradrenaline, adrenaline, angiotensin II, BK, adenosine, acetylcholine, serotonin and histamine during SMA-H20% were either unchanged or attenuated with respect to those produced under baseline conditions. Fig. 4 shows the results ofexperiments conducted on rabbits of Groups J-N (see Table I ). The results observed in Group K, which received only a saline infusion, were not significantly different from those recorded in Group F (SMA-H20% alone). In fact, the data shown for portal levels of NO in Group K are also representative of the portal NO trends 
n=8 in each group; "Surgical procedures alone; 'Intravenous injection (see text); "Intravenous infusion (see text). HP, hemodynamic parameters; MI, metabolic indices; JNO, jugular blood nitric oxide; PNO, portal (superior mesenteric) blood nitric oxide; SNO, suprahepatic blood nitric oxide; PA, physiological agonists; ENKS, leu': and meti-enkephalins; JENKS, jugular blood ENKS; ICI 174864, N,N, diallyl-tyr-aib-aib-phe-leu-Oli; AMT, ±2-amino-5,6-dihydro-6-methyl-4H -1,3 -thiazine, net.
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. observed in Group F (which were not illustrated in Fig. 3) .
. Effects ofopioid receptor blockade and inducible nitric-oxide synthase (iNOS) inhibition onjugularand portal blood levels of nitric oxide (NO). NO (as Lcitrulline) was measured in Groups K-N before (baseline, time 0) and after initiation of superior mesenteric artery hypoperfusion (SMA-H) at levels representing 20% of mean baseline SMA bloodflow (SMA-H20%
Compared with those seen in Group K, the SMA-H20%-induced changes injugular and portal blood NO levels observed in Group J (infusion of Leu"-or Met 5-ENK) were both significantly enhanced, and these effects were increasingly evident as the duration of hypoperfusion increased. In contrast, both of the opioid receptor antagonists (lCI 174864 in Group L, naloxone in Group M) tended to reverse the jugular and portal trends in NO levels seen in Group K (Fig. 4) . The more marked effects were seen with ICI 174864: after 120 min of hypoperfusion, ICI 174864 had blocked the initial rise injugular NO and reduced it to levels similar to those measured at baseline (i.e., before hypoperfusion), where it remained through the 240 th min of hypoperfusion. A similar reversal of the decreasing levels in portal blood was observed.
The iNOS inhibitor, AMT (used in Group N), also reduced jugular NO levels (AMT~naloxone < ICI 174864) but had no significant effects on portal concentrations (Fig A ) .
SMA-H20%-induced shock: hemodynamic effects of opioid receptor blockade and iNOS inhibition
As shown in Fig. 5 , cardiovascular function was improved by ICI 174864 and, to lesser extents, by naloxone and AMT. These effects were associated with significantly longer survival (particularly in ICI 174864-treated rabbits, which were still alive after 420 min of SMA-H20%) compared with that recorded in Group K (saline) (death at 180 min). Table III summarizes the results obtained in Groups O-S. Compared with results observed in the saline control Group (0), hemodynamic parameters were not significantly improved by fenoprofen (Group P), hydrocortisone (Group Q) or nor-binaltorphimine (Group R), and in all four groups death occurred within the fourth hr (240 min) of SMA-H20%. In contrast, naltrindole was as effective as ICI 174864 in improving hemodynamics, and survival in Group S was prolonged (sacrifice after 420 min).
SMA-H20%-induced shock: hemodynamic effects of drugs
DISCUSSION
With respect to SAO models, the splanchnic artery hypoperfusion model we used provides a more faithful reproduction of the diminished BF to splanchnic tissues (i.e., intestine) observed during systemic shock states. Use of this model in the present study allowed us to confirm the hypothesis advanced by others that splanchnic hypoperfusion can provoke systemic shock and favor its progression to irreversible stages (9) (10) (11) (12) (13) (14) (15) 34) . In fact, 75%-80% reductions in mean SMA BF provoked irreversible systemic shock that invariably led to death within 5-4 hrs, respectively. We have previously shown that SMA-H35% produces hypodynamic shock in mongrel dogs, with death occurring within 240 min (27) . The responses to both SMA-H25% and SMA-H20% included an initial phase of hemodynamic compensation (despite the reduced cardiac output). This phase lasted at least 2 hrs and was associated with increased peripheral extraction of oxygen and metabolic acidosis, and Ap02 remained high, at least through the 3 rd hr. During SMA-H20%, closer chronological correlation was observed between metabolic derangements, which were probably accentuated by systemic hypodynamism (low Vp02 values), and hemodynamic changes. Impaired myocardial contractility, more than the concomitant bradycardia, appeared to be responsible for both low systemic BF and hemodynamic irreversibility (9, II, 13, [35] [36] [37] [38] . The development of SMA-H20%-induced shock was accompanied by NO changes in both the jugular and portal blood. Increasing jugular levels of NO were associated with decreases in HR, dP/dt, SVI and ABF. The HR and SVI changes were initially counterbalanced by increased arterial resistance so there was no significant decrease in BP for at least 60 min. Subsequently, this arterial vasoconstriction (probably reflex in nature) was overcome by a precipitous decline in cardiac output, and BP dropped. These effects are consistent with NO's well known effects on cardiac inotropism, HR and BP (18-19, 35, 38-42) , and they suggest that cardiac output may be reduced by plasma NO concentrations lower than those determining arterial vasodilatation. The reduced levels of NO in portal blood can probably be attributed to splanchnic vasoconstriction triggered by local hypoperfusion. It is interesting to note that arterial vasoconstriction and venous dilatation are influenced by NO-mediated ENK interactions with the reninangiotensin and kallikrein-kinin systems (18, 43) . The prevention of hypodynamic shock by the 0-opioid receptor antagonist ICI 174864 can be attributed to its antagonism of cardiovascular responses to ENKs, which are the specific physiological activators of o-opioid receptors (16) (17) (18) , and to ENK-induced increases in plasma NO (18) (19) (20) (21) . Indeed, the increasing severity of the hypodynamic changes paralleled progressive increases in jugular plasma levels of ENKs and NO. The more limited protection afforded by naloxone probably reflects its lower affinity and specificity for this class of opioid receptors (25, 44) , and no effects were seen with norbinaltorphimine, which is an antagonist of K (K j ) -opioid receptors. Contributions by other classes appear unlikely. The E-opioid receptors (which are preferentially activated by l3-endorphin -as are those of the u.class) are not significantly expressed in cardiovascular tissues, and the rr-opioid receptors have been shown to bind benzomorphanes and other drugs, but not physiological opioid peptides (16, 32) .
The specificity of ENK involvement in shock induction is further underlined by the effects observed with naltrindole, another selective o-opioid receptor antagonist, fenoprofen, and hydrocortisone. Moreover, of all the physiological agonists we tested, the ENKs were the only ones whose cardiovascular effects were significantly potentiated (with respect to those produced at baseline}. Exogenous ENK administration also accentuated the increase in systemic NO levels, suggesting the presence of an additive effect withrespect to that mediated by the endogenous' ENKs. increasedin . response to SMA-H20%. Thedifferentialeffects of exogenous ENKs and ICI 174864 (or-naloxone) on portal NO levels can be attributed tointetfeli€'llce by vasoconstrictor agonists (e.g., angiotensins and endothelins) with the modulatory effects ofS-opioid receptors on pathways regulating NO synthesis and/or release in vasoconstricted vascular beds (16, (18) (19) (20) (21) (43) (44) (45) (46) .
Critical hypoperfusion of the SMA thus appears to induce irreversible hypodynamic.. shock by increasing plasma ENKs, which in' turn' produce increases in the levels of NO in' the systemic circulation (16, 21, 47) . The ENKs themselves are probably released from hypoperfused splanchnic tissues (16) (17) , i.e., the intestine. The pancreas is an unlikely source since it was normally perfused throughout the experiments. The relatively low NO concentrations in the suprahepatic blood samples tend to exclude that the liver and gut contributed directly to the increased NO levels found injugular (systemic blood) samples. Interestingly, the molecular weights of leu 5 -(-523) and met (-511) are similar to that of MDF (-500), which is reportedly produced in the pancreas, but has been only partially characterized as a peptide or related substance (9-1 I).
We have previously demonstrated that, at physiological plasma concentrations, ENKs strongly enhance the increases in plasma NO induced by BK, which supplies L-arginine for endothelial NO synthesis. The mechanism underlying this enhancement was the selective inhibition by ENKs of kininase II activity, but not that of kininase I, which cleaves the C-terminal arginine from bradykinin (19) (20) (21) . Therefore, the ENK-induced increases in plasma NO observed in our model may well be the result of a kininase I-mediated increase in the availability of BK-derived L-arginine in the endothelium, but this is not the only mechanism involved. In fact, like other NO-induced shock states (2, 6-8, 40-41, 48-50) , the one provoked by SMA-H20% was also associated with increased iNOS activity, as demonstrated by the results obtained with the iNOS inhibitor AMT. At a dose that had minimal effects on BP and plasma NO levels in the absence of SMA hypoperfusion, AMT produced a substantial decline in systemic levels of NO during SMA-H20% (without affecting portal blood levels), which was accompanied by improvement in hemodynamic parameters and prolonged survival (51). In this respect, its efficacy was similar or only slightly inferior to that of naloxone, which was in turn less effective than ICI 174864. Indeed, the discouraging results observed in previous studies on the use of NOS inhibitors have been attributed in part to the fact that the drugs used (i.e., Larginine analogs) did not selectively inhibit the inducible NOS isoform (2, (6) (7) (8) . Whether the enhanced iNOS activity is mediated by circulating ENKs, and, if so, how, are questions that cannot be answered by the data collected in our study.
In conclusion, this study demonstrates that critical arterial hypoperfusion of the gut promotes irreversible hypodynamic shock by increasing plasma levels of opioid peptides (i.e. ENKs). The selective binding of these peptides to cardiovascular c-opioid receptors leads to increased plasma levels of NO, which seem to result in part from enhanced iNOS activity. Since pronounced splanchnic artery hypoperfusion is a constant in the advanced stages of all forms of systemic shock states (52), these findings may have important therapeutic implications.
Selective blockade of the cardiovascular c-opioid receptors (22) (23) (24) (25) 53) and/ or control of increases in plasma NO levels with selective iNOS inhibitors (33, 40-41, 48, 54-59) may prove capable of improving the shock condition and/or preventing its progression to irreversible stages (60) . Our findings also shed light on possible causes of the contradictory results that have emerged from previous studies of human shock states treated with nonselective opioid receptor antagonists and/ or generic NOS inhibitors (6) (7) (8) (22) (23) (24) (25) .
